ISAL 2017 | Clinically relevant side effects of BiTE immunotherapy and other T-cell therapies

Ralf Bargou

Ralf Bargou, MD, from Würzburg University Hospital, Würzburg, Germany, summarizes the clinically relevant side effects of BiTE and other T-cell therapies at the International Symposium on Acute Leukemias (ISAL) 2017 in Munich, Germany. He explains that the toxicity profile is very similar between BiTE and CAR T-cell therapy, with flu-like symptoms being the most frequent adverse event. In non-Hodgkin lymphoma (NHL), the dose limiting toxicity were side effects of the central nervous system, while in acute lymphoblastic leukemia (ALL), particularly in those patients with a high leukemic load, the most clinically relevant side effect was cytokine release syndrome. Prof. Bargou highlights that in the majority of cases, the side effects are reversible and clinically well manageable.

Share this video